SCHEMBL113218

SCHEMBL113218

CC(C)(C)OC(=O)N1CCCN(c2ccc3nc(C(=O)c4ccnc(Br)c4)[nH]c3n2)CC1

nearest known ligand 0.45

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 1/20 0.45
▸ CKS1B P61024 2/20 0.44
▸ SKP1 P63208 2/20 0.44
▸ SKP2 Q13309 2/20 0.44
▸ PDE10A Q9Y233 2/20 0.43
▸ TBK1 Q9UHD2 7/20 0.41
▸ GALR2 O43603 1/20 0.39
▸ GALR1 P47211 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ GPR119 Q8TDV5 1/20 0.39
▸ ACHE P22303 1/20 0.38
▸ NAMPT P43490 1/20 0.38
▸ KIT P10721 1/20 0.38
▸ WNT3A P56704 1/20 0.38
▸ DDB1 Q16531 1/20 0.37
▸ CRBN Q96SW2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL110796 0.97 MAP4K4 (0.48) MAP4K4CKS1BSKP1SKP2PDE10A
SCHEMBL2143504 0.88 CKS1B (0.47) MAP4K4CKS1BSKP1SKP2PDE10A
SCHEMBL109900 0.84 CDK4 (0.42) MAP4K4CKS1BSKP1SKP2PDE10A
SCHEMBL27897985 0.83 ALDH1A1 (0.36) MAP4K4PDE10AMEN1KMT2A
SCHEMBL110934 0.82 CDK4 (0.53) MAP4K4CKS1BSKP1SKP2PDE10A
SCHEMBL112531 0.80 PDE10A (0.41) PDE10ATBK1GPR119
SCHEMBL114897 0.80 CDK4 (0.44) MAP4K4CKS1BSKP1SKP2PDE10A
SCHEMBL160571 0.79 CDK4 (0.55) MAP4K4CKS1BSKP1SKP2PDE10A
SCHEMBL174119 0.75 MAP4K4 (0.56) MAP4K4CKS1BSKP1SKP2PDE10A
SCHEMBL112530 0.75 PDE10A (0.38) PDE10ATBK1DDB1CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2424843-B1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2014-03-26 — — EP disclosed
US-8598217-B2 Imidazole derivatives and their use as modulators of cyclin dependent kinases ASTEX THERAPEUTICS LTD. (GB) 2013-12-03 — — US disclosed
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-04-26 — — US disclosed
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-04-26 — — US disclosed
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES ASTEX THERAPEUTICS LIMITED (GB) 2012-04-26 — — US disclosed
EP-2424843-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES Novartis AG (CH) 2012-03-07 — — EP disclosed
WO-2010125402-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2010-11-04 — — WO disclosed
WO-2010125402-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES NOVARTIS AG (CH) 2010-11-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101064-A1 IMIDAZOLE DERIVATIVES AND THEIR USE AS MODULATORS OF CYCLIN DEPENDENT KINASES CDK3, CCNI, CDK1 MAP4K4 137/4885CKS1B 21/4885SKP1 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback